aifollow.news
Back TechCrunch AI 报道
TechCrunch AI 报道· · Original publication time AI score40

Science Corporation raises $400 million to pursue US approval for its vision deviceMachine translation

Science Corporation 融资 4 亿美元,推进视觉植入设备在美国获批

AI-assisted summary

Science Corporation said it raised a $400 million Series D; a person familiar with the deal told TechCrunch that investors valued it at $3.5 billion. Its PRIMA vision device is approved in Europe and available in Germany, and helps people with age-related macular degeneration recover some vision. The company plans to use the funding to seek authorization for the device in the US under a pathway for rare conditions.

Article · Original

Science Corporation , the medical technology start-up founded by former Neuralink president Max Hodak in 2021, raised a $400 million Series D, the company said in a blog post .

Investors in the new round valued the company at $3.5 billion, a person familiar with the deal told TechCrunch. Those backers included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

Hodak, who talked his way into a graduate neuroscience lab as a college student and has pursued biotechnology ever since, co-founded Science to leverage new technologies to understand and interact with the brain.

Science’s first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, as well as being trialled for new conditions.

Hodak announced that the device is now being trialled for patients with another blindness-causing condition, Stargardt’s disease, while onstage at TechCrunch Disrupt.

With the funding, the company aims to bring the device to the United States through the FDA’s Humanitarian Device Exemption, which lets experimental medical technology be used to treat rare conditions. Science has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough to let them seek approval to use the device on people in the US.

Still, the startup’s big ambition and founding purpose is connecting directly to the human brain through a bio-hybrid sensor built from a combination of cultured neurons and silicon. The company is currently designing initial human trials of the device with Yale neurosurgery professor Murat Günel, who told TechCrunch it could offer potential treatments for Parkinson’s disease, among other brain injuries and illnesses.

Found an error? Send a correction